This clinical trial studies how well endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) after positron emission tomography/computed tomography (PET/CT) scan works in diagnosing patients with stage I-IIA non-small cell lung cancer evaluated for stereotactic body radiation therapy (SBRT). Performing EBUS-TBNA after PET/CT scan may help doctors learn more about the accuracy and ways to find early stage lung cancer.
PRIMARY OBJECTIVES: I. To assess the use of EBUS-TBNA after a PET/CT as a means of improving the accuracy of lymph node staging in patients considered for SBRT. SECONDARY OBJECTIVES: I. To assess the usefulness of PET/CT as a diagnostic test in identifying N1 versus N0 staging. II. To compare survival and recurrence rates in patients with discordant PET/CT and EBUS-TBNA. III. To describe EBUS-TBNA and SBRT related complications. OUTLINE: Patients undergo EBUS-TBNA before SBRT. After completion of study, patients are followed up at 6 weeks, then every 3 months for the first 2 years then twice a year for the following 3 years, and annually thereafter.
Study Type
OBSERVATIONAL
Enrollment
150
Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) performed after PET/CT, and before participant receives stereotactic body radiation therapy (SBRT). EBUS-TBNA results compared with the results of PET/CT.
University of Texas MD Anderson Cancer Center
Houston, Texas, United States
Lymphnode Staging Accuracy
The use of EBUS-TBNA after a PET/CT as a means of improving the accuracy of lymphnode staging in patients considered for SBRT estimated as the proportion of patients identified concordantly as having N0 disease with both PET/CT and EBUS-TBNA.
Time frame: 1 day
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.